07:10 EST Vanda Pharmaceuticals (VNDA) down 11% to $7.55 after FDA rejects sNDA for hetlioz
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals: FDA says sNDA for hetlioz can’t be approved
- Vanda Pharmaceuticals price target raised to $22 from $20 at H.C. Wainwright
- Midday Fly By: Nvidia said to see strong H200 demand in China
- Morning Movers: Nvidia up as report points to strong demand in China
- Video: Nvidia responding to strong demand for H200 in China